James Balkovec - Cidara Therapeutics VP Research
| CDTX Stock | USD 20.21 0.01 0.05% |
Insider
James Balkovec is VP Research of Cidara Therapeutics
| Address | 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 |
| Phone | 858 752 6170 |
| Web | https://www.cidara.com |
Cidara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1566) % which means that it has lost $0.1566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5339) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cidara Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 2.93 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Cidara Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 6.5 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 767 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr III | Cue Biopharma | 48 | |
| BS CPA | Inhibrx | 42 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Quinn Deveraux | Inhibrx | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Susan MS | Eliem Therapeutics | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Steven Almo | Cue Biopharma | 63 | |
| Mark Lappe | Inhibrx | 57 | |
| Kenneth MD | Cue Biopharma | 64 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| , MBA | Molecular Partners AG | 51 | |
| JD MSc | Cue Biopharma | 61 | |
Management Performance
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.16 |
Cidara Therapeutics Leadership Team
Elected by the shareholders, the Cidara Therapeutics' board of directors comprises two types of representatives: Cidara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cidara. The board's role is to monitor Cidara Therapeutics' management team and ensure that shareholders' interests are well served. Cidara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cidara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carol Waldo, VP Assurance | ||
| Preetam MBA, CFO Officer | ||
| James Balkovec, VP Research | ||
| Jeffrey Stein, Chief Executive and President and Executive Director | ||
| Taylor Sandison, Acting Chief Medical Officer | ||
| SPHR CCP, Senior Culture | ||
| Jim MBA, Chief Officer | ||
| Kevin Forrest, Founder, CFO, COO and Treasurer | ||
| Laura Navalta, Senior Vice President - Clinical Operations | ||
| Shane Ward, COO Secretary | ||
| Leslie Tari, Chief Officer | ||
| Les Tari, Vice President - Discovery Research | ||
| MD JD, Senior Development | ||
| MPH MD, Chief Officer |
Cidara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cidara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.53 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (2.11) % | ||||
| Operating Margin | (36.76) % | ||||
| Current Valuation | 97.52 M | ||||
| Shares Outstanding | 10.94 M | ||||
| Shares Owned By Insiders | 4.70 % | ||||
| Shares Owned By Institutions | 51.86 % | ||||
| Number Of Shares Shorted | 49.83 K | ||||
| Price To Earning | (2.21) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.